An observational study in Breast Cancer, Metastatic and Artifical Intelligence, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Not yet recruiting at 1 site in China. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Observational
Retrospectively collect the clinical data, breast MRI images, breast ultrasound images and reports, laboratory indicators (such as CA199, CA153, CA125, CEA/AFP), pathological diagnosis results, HE staining images, and existing immunohistochemical results (including CD8A, KPT5, GFRA1, PFKP, ER/PR percentage, Her-2 expression, Ki-67 index, etc.) of patients pathologically confirmed with or excluded from breast cancer in our center between January 2019 and December 2024. For biopsy specimens from patients diagnosed with breast cancer and immunohistochemically confirmed as HR+/Her-2+ during the same period, additional immunohistochemical staining for CD8A, KPT5, GFRA1, and PFKP should be performed, with images and results collected.
The collected basic clinical information, imaging data, pathological findings, and laboratory metrics of patients will serve as candidate inputs. Units of measurement will be standardized, and missing data will be imputed using the multiple imputation by chained equations algorithm. Data harmonization will employ the Box-Cox algorithm, while min-max scaling will be used for standardization. The adaptive synthetic sampling method with a balance ratio of 0.5 will address data imbalance. For the collected patient data, deep learning will be applied to screen features from the images, combined with clinical significance to identify malignant risk factors. A neural network classifier will be trained on the training set data, with independent variables including breast MRI/ultrasound images, CA199, CA153, CA125, AFP/CEA, etc., and dependent variables including breast cancer status and subtype. Pathological biopsy results will be set as the validation standard.
Model tuning will be conducted on the validation set to construct a breast cancer prediction model. It should be noted that as a single-center study, the results have limited generalizability. The further optimization and evaluation plan for the model involves using breast disease screening data from external centers for validation and refinement, evaluating the model's practical impact on clinical decision-making, and continuously tracking and optimizing its performance.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 900 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 115 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Retrospectively collect the clinical data, breast MRI images, breast ultrasound images and reports, laboratory indicators (such as CA199, CA153, CA125, CEA/AEP), pathological diagnosis results, HE staining images, and existing immunohistochemical results (including CD8A, KPT5, GFRA1, PFKP, ER/PR percentage, Her-2 expression, Ki-67 index, etc.) of patients who were pathologically confirmed with breast cancer or excluded from breast cancer in our center between January 2019 and December 2024.
For biopsy specimens from patients diagnosed with breast cancer and immunohistochemically confirmed as HR+/Her-2+ between January 2019 and December 2024, additional immunohistochemical staining for CD8A, KPT5, GFRA1, and PFKP should be performed, and the immunohistochemical images and results should be collected.
Exclusion Criteria:
Other: bulid primary AI model
Other: verdict model and develop its function
For the collected patient data, deep learning is used to perform feature screening on the selected or collected images, and malignant risk factors are determined by combining clinical significance. A neural network classifier is trained on the training set data. Variable selection: independent variables (breast MRI images, breast ultrasound images, indicators such as CA199, CA153, CA125, AFP/CEA, etc.), dependent variables (whether suffering from breast cancer and breast cancer subtypes), and the verification accuracy standard is set as the pathological biopsy result.
The accuracy of a breast cancer prediction model is typically evaluated using multiple metrics that assess its performance in different aspects
AUC (Area Under the ROC Curve)
Time frame: Baseline-AUC1 Perioperative/Periprocedural-AUC2
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University